TG Therapeutics at Jefferies Conference: Strategic Market Moves

At the Jefferies Global Healthcare Conference 2025, TG Therapeutics (TGTX) CEO Mac Weiss outlined the company's strategy to dominate the CD20 MS market with BREONVI, projecting revenue to increase from $310 million last year to $560 million this year while incrementally increasing operating expenses. The company aims to become the leading market share holder through competitive pricing, an expanded commercial team, and a direct-to-consumer campaign to boost patient awareness, with a SubQ version of BREONVI planned for potential filing in the first half of 2027 and approval by mid-2028 to compete in the SubQ market.

Analysis

TG Therapeutics (TGTX) presented an ambitious strategy at the Jefferies Global Healthcare Conference, aiming for market leadership in the CD20 Multiple Sclerosis (MS) segment with its product BREONVI. The company projects a significant revenue increase from $310 million last year to $560 million this year, prioritizing top-line growth and market share expansion over immediate profitability. This growth is supported by a strategy encompassing competitive pricing, a doubling of its commercial team to enhance clinician outreach, and a new direct-to-consumer campaign designed to elevate BREONVI's patient awareness from its current mid-30% level, which trails competitors significantly. Operating expenses are expected to rise incrementally, driven by development programs including a subcutaneous (SubQ) version of BREONVI, enhanced IV programs, and work on Acercell. The SubQ formulation, targeting less frequent dosing options (every two or three months), is a key future driver, with potential filing anticipated in the first half of 2027 and approval by mid-2028, positioning TGTX to compete in the currently monopolized SubQ MS market. Additionally, a pivotal trial for a combined IV dose regimen is underway, with results expected by mid-2026, aiming to improve patient convenience. The CEO, Mac Weiss, underscored that while the CD20 market share for new MS patient starts is around 50-55% and growing, IV administration remains dominant, though the SubQ segment (currently 35-40% of new starts) offers a substantial opportunity. The company is also actively buying back shares and remains open to exploring indications beyond MS, such as Myasthenia Gravis (MG), although these are not expected to substantially impact near-term OpEx.

Key Decisions for Investors

• Investors should monitor TG Therapeutics' progress in increasing BREONVI's market share and patient awareness, particularly the effectiveness of its expanded commercial team and direct-to-consumer initiatives, given the competitive landscape.
• Key catalysts to watch include clinical trial results for the combined IV dose regimen expected by mid-2026 and developmental milestones for the SubQ version of BREONVI, including data releases in H2 2025 or H1 2026, potential filing in H1 2027, and approval by mid-2028, which could significantly alter the company's market position.
• Consider the company's financial strategy of prioritizing aggressive revenue growth and market penetration, funded by increasing revenues and managed OpEx, over near-term profitability, alongside its active share repurchase program.